Time-to-failure in 1st-line endocrine therapy with ER+/HER2-metastatic breast cancer

被引：0
|
作者：
Nishimura, S. [1 ]
Akiyoshi, S. [1 ]
Koga, C. [1 ]
Oikawa, M. [1 ]
Nskamura, Y. [1 ]
Ishida, M. [1 ]
Ohno, S. [1 ]
机构：
[1] Kyushu Natl Canc Ctr, Breast Oncol, Fukuoka, Japan
来源：
BREAST | 2015年 / 24卷
关键词：
D O I：
10.1016/S0960-9776(15)70209-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P168
引用
收藏
页码：S82 / S83
页数：2
相关论文
共 50 条
  • [41] Endocrine therapy for ER-positive/HER2-negative metastatic breast cancer
    Reinert, Tomas
    de Paula, Bruno
    Shafaee, Maryam Nemati
    Souza, Pedro Henrique
    Ellis, Matthew J.
    Bines, Jose
    CHINESE CLINICAL ONCOLOGY, 2018, 7 (03)
  • [42] Biomarker analysis from a phase I study using gedatolisib plus palbociclib plus hormone therapy in ER+/HER2-metastatic breast cancer (mBC).
    Wesolowski, Robert
    Pathan, Nuzhat
    Zhu, Zhou
    Stringer-Reasor, Erica Michelle
    Han, Hyo S.
    Dees, Elizabeth Claire
    Bardia, Aditya
    Layman, Rachel M.
    Weise, Amy
    Kabos, Peter
    Lu, Janice M.
    Kern, Kenneth Alan
    Pierce, Kristen J.
    Rugo, Hope S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [43] Knowledge of tumor/blood genomic testing (NGS) and ESR1 mutations in a survey of patients with ER+/HER2-metastatic breast cancer (mBC)
    Meisel, Jane
    Sammons, Sarah L.
    Shanahan, Kelly
    Pluard, Timothy
    Kozlowski, Monica
    Carroll, Dominic
    Attias, Elizabeth
    CANCER RESEARCH, 2023, 83 (05)
  • [44] PATIENT CHARACTERISTICS AND TREATMENT PATTERNS IN ER+/HER2-METASTATIC BREAST CANCER IN THE UK: RESULTS FROM A RETROSPECTIVE MEDICAL RECORD REVIEW
    Kurosky, S.
    Mitra, D.
    Zanotti, G.
    Kaye, J. A.
    VALUE IN HEALTH, 2015, 18 (07) : A492 - A492
  • [45] Impact of endocrine therapy regimens for early-stage ER+/HER2-breast cancer on contralateral breast cancer risk
    Sarkar, Swarnavo
    Schechter, Clyde
    Kurian, Allison W.
    Caswell-Jin, Jennifer L.
    Jayasekera, Jinani
    Mandelblatt, Jeanne S.
    NPJ BREAST CANCER, 2025, 11 (01)
  • [46] IFOSFAMIDE AND MITOXANTRONE AS 1ST-LINE CHEMOTHERAPY FOR METASTATIC BREAST-CANCER
    PEREZ, JE
    MACHIAVELLI, M
    LEONE, BA
    ROMERO, A
    RABINOVICH, MG
    VALLEJO, CT
    BIANCO, A
    LACAVA, JA
    RODRIGUEZ, R
    CUEVAS, MA
    PARIS, A
    ACUNA, LR
    LANGHI, M
    LORUSSO, V
    DELENA, M
    JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (03) : 461 - 466
  • [47] Treatment of ER+/HER2+breast cancer
    Johnston, Stephen
    CANCER RESEARCH, 2023, 83 (05)
  • [48] TILs in ER+/HER2-breast cancer
    Criscitiello, C.
    Vingiani, A.
    Maisonneuve, P.
    Viale, G.
    Viale, G.
    Curigliano, G.
    ANNALS OF ONCOLOGY, 2019, 30 : 3 - 3
  • [49] Palbociclib After CDK4/6i and Endocrine Therapy (PACE): A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for Endocrine Pre-treated ER+/HER2-Metastatic Breast Cancer
    Mayer, Erica L.
    Ren, Yue
    Wagle, Nikhil
    Mahtani, Reshma
    Ma, Cynthia
    DeMichele, Angela
    Cristofanilli, Massimo
    Meisel, Jane
    Miller, Kathy D.
    Jolly, Trevor
    Riley, Elizabeth
    Qamar, Rubina
    Sharma, Priyanka
    Reid, Sonya
    Sinclair, Natalie
    Faggen, Meredith
    Block, Caroline
    Ko, Naomi
    Partridge, Ann
    Chen, Wendy Y.
    Demeo, Michelle K.
    Attaya, Victoria
    Okpoebo, Amanda
    Liu, Yuan
    Gauthier, Eric
    Burstein, Harold
    Regan, Meredith
    Tolaney, Sara
    CANCER RESEARCH, 2023, 83 (05)
  • [50] Dose modifications of ribociclib and endocrine therapy for treatment of ER+HER2-metastatic breast cancer
    Kristensen, K. B.
    Jensen, A. B.
    Kodahl, A. R.
    Berg, T.
    Thomsen, I. M. N.
    ANNALS OF ONCOLOGY, 2021, 32 : S71 - S71
12345